066 - Actinium Pharma's Transformative Radiation Treatment. KPTI's Selinexor Approved for DLBCL!
Breaking Biotech06/23/20 • 28 min
Actinium Pharma (#ATNM) is commercializing Antibody-Radiation Conjugates (ARC) for the treatment of diseases that require conditioning regimens (Bone Marrow Transplant, Stem Cell Transplant, Adoptive Cell Therapies). The current state of total body irradiation leaves patients with significant side effects and excludes a large demographic due to potential lethality of the conditioning treatment. ATNM is testing a targeted approach that could allow for substantially more patients to be treated and reduce side effects. I go through the details of the company and talk about why the risk/reward favors longs into the next catalyst.
Karyopharm (#KPTI) recently received news that their drug Selinexor (XPOVIO) is approved for 3L DLBCL, which should drive a nice amount of revenue for the company.
Link to myeloablative therapy costs: https://www.pharllc.com/wp-content/uploads/2017/11/10-2017_Cost.pdf
If you want to help the show, you can donate here: https://tips.pinecast.com/jar/breaking-biotech You can also open an account at Tastyworks using my referral code: https://start.tastyworks.com/#/login?referralCode=ZWQ77XG2PZ
Follow me on twitter @matthewlepoire Send me an email [email protected] www.breakingbiotech.com
Disclaimer: All opinions expressed by Matt in this podcast are solely his opinions. You should not treat any opinion expressed by Matt in this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of his opinion. Matt's opinions are based upon information he considers reliable, but Matt cannot warrant its completeness or accuracy, and it should not be relied upon as such. Matt is not under any obligation to update or correct any information provided in this podcast. Past performance is not indicative of future results. Matt does not guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed in this podcast. #biotech
06/23/20 • 28 min
Episode Comments
0.0
out of 5
No ratings yet
eg., What part of this podcast did you like? Ask a question to the host or other listeners...
Post
Generate a badge
Get a badge for your website that links back to this episode
<a href="https://goodpods.com/podcasts/breaking-biotech-130757/066-actinium-pharmas-transformative-radiation-treatment-kptis-selinexo-6467857"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to 066 - actinium pharma's transformative radiation treatment. kpti's selinexor approved for dlbcl! on goodpods" style="width: 225px" /> </a>
Copy